Expertise in
24
conditions

Bruno Vincenzi-De Vincenzi

C.i.r, 
Rome, IT 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
24
conditions
C.i.r, 
Rome, IT 

Overview

Bruno Vincenzi-De Vincenzi practices practicing medicine in Rome, Italy.

Mr. Vincenzi-De Vincenzi is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Solitary Fibrous Tumor, Orchiectomy, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 485 peer reviewed articles and participating in 13 clinical trials.

Gender

Male

Locations

C.i.r, Rome, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Enrollment Status: Recruiting
Publish Date: February 25, 2026
Intervention Type: Drug
Study Drugs: Anlotinib, Decarbazine
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Enrollment Status: Completed
Publish Date: August 20, 2026
Intervention Type: Drug
Study Drug: Nirogacestat Oral Tablet
Study Phase: Phase 3
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: January 21, 2026
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients
Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients
Enrollment Status: Completed
Publish Date: December 09, 2024
Intervention Type: Drug
Study Drugs: Trabectedin, Adriamycin, Dacarbazine
Study Phase: Phase 2
Phase 2 Randomized Trial of Trabectedin + Olaparib vs. Trabectedin in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.
Phase 2 Randomized Trial of Trabectedin + Olaparib vs. Trabectedin in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.
Enrollment Status: Completed
Publish Date: December 04, 2024
Intervention Type: Drug
Study Drugs: Trabectedin, Olaparib
Study Phase: Phase 2
HEPANOVA: a Phase II Trial of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC)
HEPANOVA: a Phase II Trial of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC)
Enrollment Status: Completed
Publish Date: November 14, 2024
Intervention Type: Device, Drug
Study Drug: Sorafenib
Study Phase: Phase 2
ERibulin in Advanced Solitary Fibrous Tumor, an ItaliaN Sarcoma Group Phase II Study (ERASING)
ERibulin in Advanced Solitary Fibrous Tumor, an ItaliaN Sarcoma Group Phase II Study (ERASING)
Enrollment Status: Completed
Publish Date: September 20, 2024
Intervention Type: Drug
Study Drug: Eribulin
Study Phase: Phase 2
Follow-up in Low Risk Gastrointestinal Stromal Tumors (GISTs) - Retrospective Analysis of Clinical Features and Outcomes
Follow-up in Low Risk Gastrointestinal Stromal Tumors (GISTs) - Retrospective Analysis of Clinical Features and Outcomes
Enrollment Status: Completed
Publish Date: February 01, 2024
Intervention Type: Other
Phase II, Single Arm, Non-randomized and Multicenter Clinical Trial of Regorafenib as a Single Agent in the First-line Setting for Patients With Metastatic and/or Unresectable KIT/PDGFR Wild Type GIST
Phase II, Single Arm, Non-randomized and Multicenter Clinical Trial of Regorafenib as a Single Agent in the First-line Setting for Patients With Metastatic and/or Unresectable KIT/PDGFR Wild Type GIST
Enrollment Status: Completed
Publish Date: March 27, 2023
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
View 9 Less Clinical Trials

485 Total Publications

Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.
Broad baseline-variable profiling of visceral conversion in bone-only HR+/HER2 - metastatic breast cancer treated with CDK4/6 inhibitors.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 14, 2026

Frequently Asked Questions about Bruno Vincenzi-De Vincenzi

Is Bruno Vincenzi-De Vincenzi a top-rated expert for Adult Soft Tissue Sarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Bruno Vincenzi-De Vincenzi is classified as an Elite expert for Adult Soft Tissue Sarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Bruno Vincenzi-De Vincenzi participate in research or clinical trials?

Yes. Bruno Vincenzi-De Vincenzi has published 485 articles and abstracts on conditions like Adult Soft Tissue Sarcoma. You can view a list of Bruno Vincenzi-De Vincenzi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Vincenzi-De Vincenzi's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 44 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile